Cervical dysplasia in a patient with multiple sclerosis treated with natalizumab.
-
アブストラクト We describe one report of a cervical dysplasia in a patient receiving natalizumab for multiple sclerosis. Other cases were identified in the WHO's global individual case safety report database, VigiBase((R)) . These data underline the importance of monitoring HPV infection in patients with MS treated with natalizumab. ジャーナル名 Fundamental & clinical pharmacology 投稿日 2018/6/24 投稿者 Durrieu, Genevieve; Dardonville, Quentin; Clanet, Michel; Montastruc, Jean-Louis 組織名 Service de Pharmacologie Medicale et Clinique, Centre Midi-Pyrenees de;PharmacoVigilance, de Pharmacoepidemiologie et d'Informations sur le Medicament,;Pharmacopole Midi-Pyrenees, INSERM, UMR 1027, CIC INSERM 1436, Toulouse, France.;Service de Neurologie, Centre Hospitalier Universitaire, Toulouse, France. Pubmed リンク https://www.ncbi.nlm.nih.gov/pubmed/29935014/ -
お問合わせ
検索
メルマガ登録
